Efficacy and Safety of Direct Oral Factor Xa Inhibitors in 795 Morbidly Obese Patients
نویسندگان
چکیده
منابع مشابه
Oral direct factor Xa inhibitors.
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynamics and metabolism. Consequently...
متن کاملcontinuing education Oral , Direct Factor Xa Inhibitors and Thromboembolic Disorders
pon successful completion of this article, the pharmacist should be able to: 1. List the advantages and disadvantages of currently available anticoagulants. 2. Discuss the role of Factor Xa (FXa) in the coagulation cascade and the rationale for selected FXa inhibition as a target for drug development. 3. Discuss the pharmacology of apixaban and rivaroxaban: mechanism of action, pharmacokinetics...
متن کاملOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
BACKGROUND Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of...
متن کاملA New Oral Direct Factor Xa Inhibitor
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملOral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing anticoagulants are effective, their use is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment. Therefore, there is an urgent need for novel, oral agents with a predictable anticoagulant action. Because of its ke...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2018
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2018-99-116396